Baxter International Inc. Q1 2007 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2007. Baxter International Inc. operates in three primary segments: BioScience, Medication Delivery, and Renal. A significant corporate event during this period was the divestiture of the Transfusion Therapies (TT) business to Fenwal Inc. (an affiliate of TPG Capital) on February 28, 2007.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Sales | $2,675 million | $2,409 million |
| Gross Margin | 47.3% | 43.7% |
| Net Income | $403 million | $282 million |
| Diluted EPS | $0.61 | $0.43 |
| Operating Cash Flow | $215 million | $305 million |
| Cash and Equivalents | $2,384 million | $881 million (end of period) |
| Total Debt (Short-term + Long-term) | $2,720 million | $2,741 million (Dec 31, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% year-over-year, driven by 15% growth in BioScience, 8% in Medication Delivery, and 6% in Renal. Foreign currency fluctuations contributed a 3 percentage point benefit.
- Profitability: Net income rose 43% to $403 million. Gross margin improved by 360 basis points to 47.3%, aided by a favorable product mix (ADVATE, IVIG), manufacturing efficiencies, and the absence of $18 million in COLLEAGUE pump costs recorded in Q1 2006.
- Divestiture Impact: The company recorded a pre-tax gain of $58 million on the sale of the TT business, partially offset by $35 million in related severance and transition charges. Net cash proceeds were $473 million.
- Cash Flow: Operating cash flow decreased to $215 million from $305 million, primarily due to increased working capital requirements (receivables and inventories) and the timing of tax benefits.
- Debt Reduction: Net interest expense dropped 72% to $5 million due to lower average debt levels and higher cash balances.
Guidance, Outlook, and Risks
- Tax Rate: Management anticipates an effective tax rate of 20% to 21% for the full year 2007. The Q1 rate was 23.8%, elevated by the tax impact of the TT divestiture gain.
- COLLEAGUE Infusion Pumps: Shipments remain held in the U.S. pending FDA-mandated modifications. The company received FDA clearance for modifications in February 2007 and authorization to modify existing pumps in May 2007. Sales have resumed in all international markets.
- Legal Contingencies: Significant ongoing litigation includes patent disputes (ADVATE, Sevoflurane, GAMMAGARD), product liability claims (mammary implants, plasma-based therapies), and securities class actions. Management believes reserves are adequate and outcomes are not expected to have a material adverse effect on the consolidated financial position.
- Capital Allocation: The Board authorized an additional $2.0 billion share repurchase program in February 2007. The company repurchased $270 million of stock in Q1 2007. Dividends were increased by 15% annually, with a shift to a quarterly payment schedule.
Investor Verification Checklist
- TT Divestiture Accounting: Verify the classification of the $58 million gain and $35 million charge, and the impact on segment reporting.
- COLLEAGUE Pump Resolution: Monitor the timeline for completing pump modifications in the U.S. and the resumption of domestic sales.
- Working Capital Trends: Review the increase in Days Sales Outstanding (55.3 days) and inventory levels, particularly in the Medication Delivery segment.
- Legal Reserves: Assess the adequacy of reserves for the mammary implant and plasma-based therapy litigation, noting the uncertainty of insurance coverage.
- Share Repurchase Capacity: Confirm the remaining authorization under the $1.5 billion (2006) and $2.0 billion (2007) programs.